SS
LCTX icon

Simplicity Solutions’s Lineage Cell Therapeutics LCTX Stock Holding History

Simplicity Solutions’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-48,000
Closed -$72K – 1145
2023
Q1 		$72K Buy
+48,000
New +$67K ﹤0.01% 1080

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Simplicity Solutions's LCTX Position: Q2 2023 in Review

Simplicity Solutions sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 48,000 shares — an estimated $72K sold.

Simplicity Solutions first reported a position in LCTX in Q1 2023 and held it in 1 quarter. The position peaked at $72K in Q1 2023. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • Simplicity Solutions reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Simplicity Solutions sold 48,000 Lineage Cell Therapeutics shares in Q2 2023, an estimated $72K.
  • Simplicity Solutions first reported a position in Lineage Cell Therapeutics in Q1 2023 and held it in 1 quarter.
  • Simplicity Solutions's Lineage Cell Therapeutics position peaked at $72K in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on Simplicity Solutions's 13F filing for Q2 2023, filed 26 Jul 2023.